GRACE :: Lung Cancer

relapsed SCLC

Denise Brock

ASCO 2017 – Lung Cancer – What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?

Share
H. Jack West, MD
Medical Director
Thoracic Oncology Program Swedish Cancer Institute
President & CEO, GRACE
Matthew Gubens, MD
Thoracic Oncologist
Thoracic Surgery and Oncology Clinic
UCSF Helen Diller Family Comprehensive Cancer Center
Jyoti D. Patel, MD
Director Thoracic Oncology
University of Chicago Medicine

 

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?



 

 Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
   
                   

 


Dr West

Small Cell Lung Cancer Update, from ASCO 2012 Lung Cancer Highlights Program

Share

Here’s the last portion of Dr. Socinski’s presentation, which covers two important trials in small cell lung cancer (SCLC) presented at ASCO 2012.  The first was a SWOG trial of the standard second line agent topotecan (here given on a weekly schedule) either alone or combined with the antiangiogenic agent Eylea (aflibercept).  The results of this trial were generally considered encouraging enough to warrant further study, and you can learn the details from his talk.

He also covers an important study done by the Japanese Cooperative Oncology Group (JCOG), which compared cisplatin/amrubicin to cisplatin/irinotecan, which is standard first line therapy for extensive stage SCLC in Japan.  Dr. Socinski reviews the results and places them in context for us.

Below is the video and audio versions of the podcast, along with the transcript and figures.

Dr. Socinski ASCO LC Highlights 2012 SCLC Update Audio Podcast

Dr. Socinski ASCO LC Highlights 2012 SCLC Update Transcript

Dr. Socinski ASCO LC Highlights 2012 SCLC Update Figs

Continue reading


Dr West

Top 5 Notable Abstracts in the Small Cell Lung Cancer and Stage I-III NSCLC Track

Share

Here are the 5 presentations at ASCO in stage I-III NSCLC and small cell lung cancer that I think are most interesting and relevant.  You’ll note that several are “negative” trials — blockbusters are hard to come by here — but even trials that tell us what not to do are important.   And there are some hints of new approaches that could improve outcomes for patients.

Continue reading


Dr West

First ASCO Highlights Podcast: Dr. Pinder on Small Cell, Early Stage NSCLC, and Mesothelioma

Share

Several weeks ago, we were fortunate enough to have Dr. Mary Pinder (alternately referred to as Pinder-Schenck) from the H. Lee Moffitt Cancer Center in Tampa join as the first of two speakers reviewing highlights in thoracic oncology from ASCO. She covered several key presentations in small cell lung cancer, early stage non-small cell lung cancer, and mesothelioma. Here’s the audio and video versions of the podcast, along with the transcript and figures (a zip file to decompress, since it was too big in unzipped form to upload) for this program:

pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-audio-podcast

pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-transcript

pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-figures

Continue reading


Dr West

Amrubicin for SCLC: Recap from ASCO

Share

Though there are many presentations to discuss in the wake of ASCO, we’ll need to pace ourselves on these. I and some of the other faculty members will offer thoughts on some of these in the coming weeks, and we also have our upcoming post-ASCO review on June 23rd (click here to learn more and sign up for this free online program).

Today we saw the results of a couple of long-awaited trials of treatment approaches that represented a couple of the more promising concepts for moving forward in our treatment of extensive SCLC, and I’ll cover the first of these today (though only with the benefit of my notes, rather than as many details as I’d like, so these comments are subject to revision and added details later). Amrubicin has been the subject of some prior discussion here, but that discussion focused on smaller, phase II trials; we’ve needed the results of a randomized phase III trial that directly compares the chemo agent amrubicin as a single agent to our current standard for Hycamtin (topotecan). The ACT-1 trial in enrolled 637 patients with extensive disease SCLC who had all received first line therapy and then relapsed — the trial included patients who had a “sensitive” relapse, 3 or more months after prior chemo had ended, as well as “resistant” relapse, which is marked by progression within 3 months of prior chemo ending (pretty evenly split at nearly 50/50 on the trial). Patients were randomized 2:1 to either amrubicin at 40 mg/m2 IV on days 1-3 of a 21 day cycle, or topotecan at 1.5 mg/m2 IV days 1-5 of a 21 day cycle.

Continue reading


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243